Who is sponsoring NCT00447122?

NCT00447122 is sponsored by Brown University.

What drugs are being tested in NCT00447122?

Interventions in NCT00447122: Gemcitabine 1000mg/m2 30 minutes, Lapatinib 1000mg/d, Lapatinib 1500mg/d, Gemcitabine 1000mg/m2 100minutes, Oxaliplatin 100mg/m2.

What condition does NCT00447122 study?

NCT00447122 studies Metastatic Pancreatic Cancer.

Is NCT00447122 still recruiting?

NCT00447122 is currently terminated. Last updated 5 January 2022.

Are results published for NCT00447122?

Yes — primary outcome results have been posted to ClinicalTrials.gov. See the outcomes section above for details.

Last reviewed 2022-01-05 · How we verify

NCT00447122

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

BrUOG-PA-209: Lapatinib and Gemcitabine for Metastatic Pancreaticobiliary Cancer: A Phase I Study #108181

Terminated Phase 1 Results posted Last updated 5 January 2022

What this trial tests

Phase 1 trial testing Gemcitabine 1000mg/m2 30 minutes in Metastatic Pancreatic Cancer in 25 participants. Terminated before completion.

Timeline

1 March 2007

Primary endpoint
1 August 2008

1 August 2008

Quick facts

Lead sponsor	Brown University
Phase	Phase 1
Status	Terminated
Study type	INTERVENTIONAL
Allocation	non randomized
Design	sequential
Masking	none
Primary purpose	treatment
Enrollment	25
Start date	1 March 2007
Primary completion	1 August 2008
Estimated completion	1 August 2008
Sites	1 location across United States

Drugs / interventions tested

Gemcitabine 1000mg/m2 30 minutes — full drug profile →
Lapatinib 1000mg/d — full drug profile →
Lapatinib 1500mg/d — full drug profile →
Gemcitabine 1000mg/m2 100minutes — full drug profile →
Oxaliplatin 100mg/m2

Conditions studied

Metastatic Pancreatic Cancer — all drugs for Metastatic Pancreatic Cancer →

Sponsor

Brown University

Who can join

18 and older, any sex, with Metastatic Pancreatic Cancer. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Overall Survival for Patients With Metastatic Pancreatic Cancer.
Time frame: Date of study entry until the date of death, up to 12 months.

Sponsor's own description

Phase I study of lapatinib and gemcitabine for patients with metastatic pancreaticobiliary cancer.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Resistance to Gemcitabine in Pancreatic Ductal Adenocarcinoma: A Physiopathologic and Pharmacologic Review.
Koltai T, Reshkin SJ, Carvalho TMA, Di Molfetta D, et al · · 2022 · cited 77× · PMID 35626089 · DOI 10.3390/cancers14102486

Verify or expand the search:

Other recruiting trials for Metastatic Pancreatic Cancer

Currently open trials in the same condition.

NCT07409272 — A Study to Evaluate the Effectiveness and Safety of Setidegrasib, Given With Either mFOLFIRINOX or NALIRIFOX Chemotherap · Phase 3 · recruiting
NCT06861088 — The Effect of Kinisoquin™ on Thromboembolic Events in Patients With Metastatic or Locally Advanced Pancreatic Cancer · Phase 3 · recruiting
NCT06843551 — The Miami "EMPIRE" Trial - Eradication of Metastatic Pancreatic Cancer With Immuno-Radiation · Phase 2 · recruiting
NCT06951997 — QL1706 Plus Chidamide, AG as First-line Treatment for Metastatic Pancreatic Cancer · Phase 2 · recruiting
NCT06533332 — A Phase 1 Trial of ERX-315 in Participants With Advanced Solid Tumors · Phase 1 · recruiting

Other Brown University trials

Trials by the same sponsor.

NCT07502872 — TPG: Tafasitamab, Polatuzumab Vedotin, and Glofitamab as First-line Therapy for Diffuse Large B-cell Lymphoma and High-g · Phase 2 · not yet recruiting
NCT07118618 — Probenecid Administration for Alcohol Craving and Consumption · Phase 2 · recruiting
NCT07398443 — Using Novel Behavioral Economic Measures to Characterize Dual Marijuana and Tobacco Use in Young Adults · NA · recruiting
NCT05901766 — Effect of Iodine-containing Multiple Micronutrient During Lactation on Infant Neurodevelopment · Phase 4 · not yet recruiting
NCT06974604 — Preventing Dato-DXd Associated Stomatitis With Dexamethasone Mouthwash, TROPION-DM · Phase 2 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT00447122 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Brown University
Last refreshed: 5 January 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00447122.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing